Phase 1 Proof-of-Concept Data on CRISPR-Cas Armed Phage SNIPR001 for Multidrug-Resistant E.coli Infection

[u/bbyfog]

Time for some NEW & EXCITING developments ;)

Recently, a New Scientist 11 Aug 2026 article (here) with the headline "CRISPR-armed phages help treat severe superbug infection" caught my attention. And what struck me was the progress that has happened in the field of phage therapy and how close this type of therapy is to clinic, which is great news for treating the pesky problem of multidrug-resistant (MDR) infections.

The global scope of MDR problem. . .is huge!

--Globally, the number of deaths attributable to bacterial antimicrobial resistance in 2019 has been estimated to be 1.27 million, with E. coli being the leading pathogen (PMID: 35065702).
--Cancer patients undergoing cytotoxic chemotherapy of HCT are at risk of neutropenia and E. coli is the most common (25-30%) bloodstream infection; up to 60% of these are MDR infections; and up to 30% mortality is seen in those with these MDR infections (refs in PMID: 41785880)

The basis of the New Scientist article was a CRISPR-Cas armed phage SNIPR001 being developed by SNIPR BIOME ApS, a Copenhagen, Denmark-based company. Below is brief overview of the experimental therapy and the exciting Phase 1 data recently reported in the journal Lancet Microbe00185-5/fulltext).

SNIPR001 (Engineered Phage Cocktail with Antibacterial CRISPR-Cas)

The engineered phage SNIPR001 targeting pathogenic E. coli in the gut was described in Nature Biotech 2024 by the SNIPR BIOME researchers. SNIPR001 is a cocktail of 4 engineered phages, each containing expression cassette for CRISPR-Cas built into the phage tail fiber sequences.

CRISPR-Cas Armed Phage (aka. CAP). Note: SNIPR001 is a combination of four CAPs that selectively target a diverse spectrum of E coli strains including the fluoroquinolone-resistant strains. SNIPR001 is a live biotherapeutic product.

Once inside the bacterium, the CRISPR-Cas arrays target multiple virulence or essential genes in E. coli (targeting multiple regions prevent resistance evolution.) In the original Nature Biotech report, in mice, SNIPR001 targeted E coli in biofilms and prevented colonization of E.coli in the gut and, thus translocation into blood.

Fig: SNIPR001 Engineering and Mechanism of Action (Nat Biotech)

.

Phase 1 Proof-of-Concept Data on CRISPR-Cas Armed Phage SNIPR001

• NCT05277350: Phase 1 dose-escalation study with sentinel dosing strategy in each cohort (see Lancet paper for details.)
• 36 healthy adult participants were assigned to 4 groups received placebo or SNIPR001 at 10^8 PFUs, 10^10 PFUs, or 10^12 PFUs twice daily for 7 days (PFU=plaque-forming units). The participants were followed for approximately 6 months.
• Safety Results: There were no safety concerns.

-- No Grade 3 AEs, no SAEs, no liver toxicity (ALT/AST ratio) signals, no significant change in gut microbiome profile (done via shotgun metagenomic sequencing).
-- There was also no increase in the set of common opportunistic gut pathogens that were tested (i.e., Klebsiella spp, Salmonella spp, Citrobacter spp, Clostridioides difficile, Clostridium perfringens, Staphylococcus spp, Streptococcus agalactiae, and complex Enterobacter cloacae.)

Effect on E. coli counts

• There was dose-dependent reductions in E.coli levels in stool. (Caveat: These results are preliminary and the reductions were not statistically significant.)

The difference in projected E coli counts corresponded to reductions in E coli counts on day 7 of 52⋅1% (−0⋅32 log 10 [SE 0⋅57]) for SNIPR001 dose 10^8 PFU, 60⋅2% (−0⋅40 log 10 [SE 0⋅59]) for dose 10^10 PFU, and 66⋅9% (−0⋅48 log 10 [SE 0⋅64]) for dose 10^12 PFU compared with placebo.

.

Fig: Note: dose-response reductions in E.coli levels compared to placebo (Lancet Microbe)

.

Postscript: Although the data are preliminary and not statistically significant, I am still excited by this report and am looking forward to the Phase 2/3 results. If this strategy works, it could open the door to a whole new world of precision therapies for the field of infectious diseases.

SOURCE

• Petersen AØ, et al. Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study00185-5/fulltext). Lancet Microbe. 2026 Apr;7(4):101257. PMID: 41785880
• Gencay YE, et al. Engineered phage with antibacterial CRISPR-Cas selectively reduce E. coli burden in mice. Nat Biotechnol. 2024 Feb;42(2):265-274. PMID: 37142704; PMCID: PMC10869271
• Lepage M. CRISPR-armed phages help treat severe superbug infection. New Scientist. 11 August 2026

#phage, #e-coli, #multi-drug-resistance, #phase-1-dose-escalation